Skip to main content

Table 1 Characteristics of the cohort at the time of the switch to an STR

From: Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

  Overall TAF/FTC/EVG/cobi TAF/FTC/RPV ABC/3TC/DTG
N = 560 n = 170 (30.4%) n = 191 (34.1%) n = 199 (35.5%)
Gender, n (%)
Female 126 (22.5) 41 (24.1) 38 (19.9) 47 (23.6)
Male 434 (77.5) 129 (75.9) 153 (80.1) 152 (76.4)
Age (years), median [IQR] 49.00 [41.00, 55.00] 48.00 [38.25, 55.00] 48.00 [40.50, 54.00] 50.00 [43.00, 55.00]
Risk group, n (%)
Heterosexual 233 (41.6) 75 (44.1) 76 (39.8) 82 (41.2)
IVDU 65 (11.6) 16 (9.4) 19 (9.9) 30 (15.1)
MSM 234 (41.8) 71 (41.8) 86 (45.0) 77 (38.7)
Other 28 (5.0) 8 (4.7) 10 (5.2) 10 (5.0)
Smoke, n (%) 220 (39.3) 77 (45.3) 65 (34.0) 78 (39.2)
Weight (kg), median [IQR] 72.00 [64.00, 80.00] 71.50 [63.05, 80.75] 73.00 [66.00, 81.00] 70.00 [63.00, 78.00]
BMI, median [IQR] 24.01 [21.97, 25.98] 23.70 [21.68, 25.86] 24.39 [22.49, 26.22] 23.94 [21.85, 25.97]
Systolic blood pressure (mmHg), median [IQR] 120.00 [110.00, 130.00] 120.00 [110.00, 130.00] 120.00 [110.00, 130.00] 120.00 [110.00, 130.00]
Diastolic blood pressure (mmHg), median [IQR] 80.00 [70.00, 80.00] 80.00 [70.00, 80.00] 80.00 [70.00, 80.00] 80.00 [70.00, 80.00]
Previous therapy duration (years), median [IQR] 10.36 [4.96, 16.88] 9.94 [3.19, 16.22] 8.71 [4.56, 15.11] 11.47 [6.70, 18.02]
Previous AIDS, n (%) 111 (19.8) 39 (22.9) 32 (16.8) 40 (20.1)
Treated with ASA, n (%) 38 (6.8) 9 (5.3) 10 (5.2) 19 (9.5)
Treated with anti-hypertensive agent, n (%) 101 (18.0) 31 (18.2) 32 (16.8) 38 (19.1)
Treated with oral hypoglycemic agents / insulin, n (%) 18 (3.2) 3 (1.8) 8 (4.2) 7 (3.5)
Treated with lipid-lowering agents other than statins a, n (%) 43 (7.7) 16 (9.4) 12 (6.3) 15 (7.5)
Treated with statins, n (%) 88 (15.7) 27 (15.9) 33 (17.3) 28 (14.1)
HCV, n (%) 121 (21.6) 28 (16.5) 40 (20.9) 53 (26.6)
HBV, n (%) 25 (4.5) 14 (8.2) 6 (3.1) 5 (2.5)
Switch from PI, n (%) 137 (24.6) 42 (24.7) 13 (6.8) 82 (41.6)
Switch from TDF, n (%) 357 (64.1) 132 (77.6) 167 (87.9) 58 (29.4)
Switch from RTV / cobi, n (%) 193 (34.5) 113 (66.5) 16 (8.4) 64 (32.2)
Switch from INI, n (%) 143 (25.5) 97 (57.1) 5 (2.6) 41 (20.6)
CD4+ (cells/mmc), median [IQR] 710.50 [560.00, 893.00] 681.00 [535.00, 878.75] 711.00 [566.50, 862.00] 744.00 [580.00, 961.00]
Creatinine (mg/dl), median [IQR] 0.90 [0.79, 1.03] 0.90 [0.79, 1.01] 0.94 [0.80, 1.04] 0.89 [0.76, 1.04]
eGFR ml/min, median [IQR] 98.49 [79.96, 118.06] 97.31 [80.67, 118.45] 101.24 [81.70, 115.49] 96.92 [75.87, 118.96]
Triglycerides (mg/dl), median [IQR] 115.00 [87.00, 166.00] 110.50 [88.50, 169.25] 110.50 [81.25, 150.25] 122.00 [91.00, 173.00]
Total cholesterol (mg/dl), median [IQR] 193.00 [171.00, 215.00] 192.50 [173.75, 213.50] 186.00 [169.00, 209.00] 200.00 [174.00, 224.00]
HDL cholesterol (mg/dl), median [IQR] 43.00 [37.00, 52.00] 43.00 [35.50, 54.00] 43.00 [37.00, 49.50] 44.00 [36.00, 52.00]
LDL cholesterol (mg/dl), median [IQR] 120.30 [101.40, 143.05] 121.80 [102.00, 140.80] 115.80 [100.75, 139.50] 121.20 [102.40, 153.90]
Framingham risk score, median [IQR] 8.25 [4.19, 16.03] 9.18 [3.92, 18.02] 7.23 [3.47, 14.11] 9.23 [5.13, 15.99]
  1. afibrates, plant stanols and sterols, ezetimibe, cholestyramine and Omega-3 polyenic acids
  2. List of abbreviations: n number, IQR Inter Quartile Range, MSM men who have sex with men, IVDU intravenous drug users, PI protease inhibitors, INI integrase inhibitors, TDF tenofovir disoproxil fumarate, HDL high density lipoprotein, LDL low density lipoprotein, CD cluster of differentiation, RTV ritonavir, cobi cobicistat, eGFR estimated glomerular filtration rate, BMI body mass index, ASA acetil salicylic acid, AIDS acquired immune deficiency syndrome, HCV hepatitis C virus, HBV hepatitis B virus, TAF tenofovir alafenamide, FTC emtricitabine, 3TC lamivudine, ABC abacavir, DTG dolutegravir, RPV rilpivirine